☆ 4.7 Article

A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

EMERGING MICROBES & INFECTIONS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Multidisciplinary

Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates

Yin-Feng Kang et al.

Summary: The RBD-conjugated nanoparticles designed in this study show promising immunization effects in mice, with higher neutralizing activity against the virus and more efficient blocking of RBD-ACE2 binding. These results suggest that the vaccine is a competitive candidate, and the carrier nanoparticles could serve as a universal platform for future vaccine development.

ACS NANO (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Erik Volz et al.

Summary: The study suggests a positive selection for the SARS-CoV-2 spike protein variant D614G in the UK, but no evidence of differences in COVID-19 mortality or clinical severity in patients infected with this variant. 614G is associated with higher viral load and younger age of patients compared to 614D.

CELL (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Tiong Kit Tan et al.

Summary: This study introduces a potential vaccine candidate against SARS-CoV-2, utilizing a synthetic virus-like particle platform to present the receptor-binding domain of the virus spike protein. The vaccine induces strong neutralizing antibody responses in mice and pigs, demonstrating thermostability and the potential for global distribution.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Cyrielle Fougeroux et al.

Summary: The study developed two SARS-CoV-2 vaccines based on capsid-like particles, showing good neutralizing antibody efficacy; mice vaccinated with the RBD-CLP vaccine demonstrated higher levels of serum anti-spike antibodies than those with soluble RBD vaccine; the RBD-CLP vaccine in mice exhibited virus neutralization antibody titers comparable to those found in patients who had recovered from COVID-19.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Recombinant protein vaccines, a proven approach against coronavirus pandemics

Jeroen Pollet et al.

Summary: This article points out that recombinant protein vaccines may become a favorable option in the context of the COVID-19 pandemic, despite being overlooked in early development, they may offer an advantage or complement under the current circumstances.

ADVANCED DRUG DELIVERY REVIEWS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson et al.

Summary: The study evaluated the immunogenicity of the Ad26.COV2.S vaccine in human participants, showing rapid induction of spike-specific humoral and cellular immune responses. Various antibody subclasses, Fc receptor binding properties, and antiviral functions were induced, along with CD4+ and CD8+ T-cell responses.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques

Hyon-Xhi Tan et al.

Summary: The study compared the immunogenicity of spike proteins (S) and receptor binding domain (RBD) in SARS-CoV-2 vaccines in mice and macaques, finding that S was highly immunogenic in mice while RBD was comparatively poor. Both S and RBD vaccines were similarly immunogenic in macaques, inducing serological neutralising activity exceeding convalescent human levels.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Immunology

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen

Vikram Srivastava et al.

Summary: The study demonstrates that immunization with recombinant RBD antigen using different adjuvants can induce potent neutralizing antibodies against SARS-CoV-2, which is crucial for developing a COVID-19 vaccine. The results also show that adjuvants have a significant impact on the dynamics of antibody induction, antibody levels, avidity, and B-cell epitopes targeted by the immune system.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemical Research Methods

Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys

Heng Li et al.

Summary: This study developed a rapid vaccine platform displaying SARS-CoV-2 spike protein receptor-binding domain on self-assembled ferritin nanoparticles, which induced specific immunity and cross-neutralizing antibodies against different strains of SARS-CoV-2. The vaccine significantly inhibited virus replication and reduced respiratory pathology damage in immunized rhesus monkeys after challenge with SARS-CoV-2 virus.

BIOCONJUGATE CHEMISTRY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang et al.

Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Prabhu S. Arunachalam et al.

Summary: This study demonstrated the effectiveness of an adjuvanted RBD-NP vaccine in inducing robust and durable neutralizing antibody responses, providing protection against SARS-CoV-2 infection, and cross-neutralizing various variants. Adjuvants such as AS03 and AS37 significantly enhanced the immunogenicity of the vaccine and have the potential to be candidates for COVID-19 vaccines.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Nicholas G. Davies et al.

Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

添加到收藏夹

Review Microbiology

The success of SARS-CoV-2 vaccines and challenges ahead

Kanta Subbarao

Summary: The development of effective SARS-CoV-2 vaccines is facing challenges in preventing asymptomatic and mild infections, potential updates required due to the emergence of variants with mutations, and concerns about the longevity of vaccine-induced immunity. Coordination in global surveillance, updating vaccines, and potential re-vaccination may be necessary to address these challenges.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Cell Biology

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2

Shiyu Sun et al.

Summary: By utilizing interferon-armed RBD to enhance antigen processing and cross-presentation, researchers have developed the I-P-R-F vaccine, which provides comprehensive protection with a single dose and elicits stronger immune responses than traditional RBD vaccines.

CELL RESEARCH (2021)

添加到收藏夹

Letter Medicine, General & Internal

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C. Wall et al.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

Hannah A. D. King et al.

Summary: The RFN-ALFQ vaccine induced robust immune responses in macaques, rapidly controlling viral replication and demonstrating good cross-neutralization activity against different SARS-CoV-2 variants. It also elicited responses against the SARS-CoV-1 virus, highlighting its broad immunogenicity for Sarbecovirus vaccine development.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Pfizer vaccine's efficacy declined from 96% to 84% four months after second dose, company reports

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Microbiology

Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19

Cheng-Pu Sun et al.

Summary: This study introduces a versatile approach that enables rapid generation of mouse models for emerging infectious diseases within a month, aiding in the study of disease mechanisms and drug development. The created mouse model for COVID-19 accurately mimicked severe cases in patients and was successfully used in drug development.

PLOS PATHOGENS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Thomas W. McDade et al.

Summary: The two-dose mRNA vaccines against SARS-CoV-2 are effective in preventing COVID-19 infection, but there is a decline in antibody levels and reduced neutralization of emerging variants three months post-vaccination, indicating the need to identify correlates of clinical protection for booster vaccination timing and indications.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Ren-Di Jiang et al.

CELL (2020)

添加到收藏夹

Article Infectious Diseases

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Yuwei Liu et al.

JOURNAL OF INFECTION (2020)

添加到收藏夹

Review Biochemical Research Methods

Self-Assembled Nanoparticles: Exciting Platforms for Vaccination

Jingdi Pan et al.

BIOTECHNOLOGY JOURNAL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19

Bicheng Zhang et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Why and How Vaccines Work

Akiko Iwasaki et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Jingyun Yang et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru et al.

SCIENCE (2020)

添加到收藏夹

Article Immunology

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Xiancai Ma et al.

IMMUNITY (2020)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine

Janice Hopkins Tanne

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Alexandra C. Walls et al.

CELL (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Potential Zika Vaccine: Encapsulated Nanocomplex Promotes Both TH1/TH2 Responses in Mice

Yan-Wei Wu et al.

ADVANCED THERAPEUTICS (2020)

添加到收藏夹

Review Immunology

Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses

Mark K. Slifka et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Li Liu et al.

JCI INSIGHT (2019)

添加到收藏夹

Review Immunology

The origins of the vaccine cold chain and a glimpse of the future

John Lloyd et al.

VACCINE (2017)

添加到收藏夹

Article Microbiology

Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model

Yi-Wen Liu et al.

FRONTIERS IN MICROBIOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

V. Stalin Raj et al.

NATURE (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Development of amphiphilic γ-PGA-nanoparticle based tumor vaccine:: Potential of the nanoparticulate cytosolic protein delivery carrier

Tomoaki Yoshikawa et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)

添加到收藏夹

Article Immunology

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination

David A. Zaharoff et al.

VACCINE (2007)

添加到收藏夹

Article Multidisciplinary Sciences

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

WH Li et al.

NATURE (2003)

添加到收藏夹

Review Immunology

Type 1 type 2 immunity in infectious diseases

B Spellberg et al.

CLINICAL INFECTIOUS DISEASES (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.